CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Avastin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00503906
NCT00503906Phase 2Completed
CompareCT.gov

A Phase II Study of Abraxane, Avastin and Gemcitabine for First Line Metastatic Breast Cancer

University of Miami·interventional·Posted Jul 19, 2007·Updated May 12, 2017

In Brief

A Phase 2 clinical trial evaluating Avastin, Gemcitabine, and 1 other intervention for Breast Cancer. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The investigators hypothesize that the combination of Gemzar®, Abraxane® and Avastin will increase the progression-free survival (PFS) in patients with first line metastatic breast cancer and in patients who received neoadjuvant and/or adjuvant chemotherapy present with definable metastatic disease, 6 or more months after primary treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 19, 2007
Enrollment StartJun 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 19.0 years ago

Interventions

Avastindrug

Gemcitabinedrug

Abraxanedrug